Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study

BACKGROUND: The FLAME study demonstrated that indacaterol/glycopyrronium (IND/GLY), the fixed-dose combination of a long-acting β(2)-agonist (LABA, IND) and a long-acting muscarinic antagonist (LAMA, GLY), was superior to salmeterol/fluticasone combination (SFC) in preventing exacerbations in COPD p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wedzicha, Jadwiga A, Zhong, Nanshan, Ichinose, Masakazu, Humphries, Michael, Fogel, Robert, Thach, Chau, Patalano, Francesco, Banerji, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261570/
https://www.ncbi.nlm.nih.gov/pubmed/28176893
http://dx.doi.org/10.2147/COPD.S125058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261570/
https://www.ncbi.nlm.nih.gov/pubmed/28176893
http://dx.doi.org/10.2147/COPD.S125058

Ejemplares similares